ZP
SPRB

Zimmer Partners’s Spruce Biosciences SPRB Stock Holding History

Zimmer Partners’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-267
Closed -$486K – 201
2020
Q4 		$486K Buy
+267
New +$443K 0.01% 116

Other funds holding SPRB

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Zimmer Partners's SPRB Position: Q1 2021 in Review

Zimmer Partners sold out of Spruce Biosciences (SPRB) in Q1 2021, closing a stake of 267 shares — an estimated $486K sold.

Zimmer Partners first reported a position in SPRB in Q4 2020 and held it in 1 quarter. The position peaked at $486K in Q4 2020. 40 funds tracked by Wall St. Rank hold SPRB as of Q1 2021.

  • Zimmer Partners reported no remaining Spruce Biosciences position as of Q1 2021 after selling out during the quarter.
  • Zimmer Partners sold 267 Spruce Biosciences shares in Q1 2021, an estimated $486K.
  • Zimmer Partners first reported a position in Spruce Biosciences in Q4 2020 and held it in 1 quarter.
  • Zimmer Partners's Spruce Biosciences position peaked at $486K in Q4 2020.
  • 40 funds tracked by Wall St. Rank held Spruce Biosciences as of Q1 2021.

Based on Zimmer Partners's 13F filing for Q1 2021, filed 17 May 2021.